5 December 2019
EMA/CAT/48305/2020
Inspections, Human Medicines Pharmacovigilance and Committees Division

Committee for Advanced Therapies (CAT)

Minutes of the meeting on 06-08 November 2019

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, the minutes are a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced that no restriction in the involvement of meeting participants in upcoming discussions was identified.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 22 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

The CAT agenda for 06-08 November 2019 meeting was adopted.

1.3. Adoption of the minutes

The CAT minutes of 09-11 October 2019 meeting were adopted.

2. Evaluation of ATMPs

2.1. Opinions

No items

2.2. Oral explanations

No items

2.3. Day 180 list of outstanding issues

No items

2.4. Day 120 list of questions

No items

2.5. Day 80 assessment reports

No items

2.6. Update on ongoing initial applications

2.6.1. Onasemnogene abeparvovec - Orphan - EMEA/H/C/004750

AveXis Netherlands B.V.; treatment of spinal muscular atrophy (SMA)

feedback from Rapporteurs

Action: for discussion

2.6.2. Onasemnogene abeparvovec - Orphan - EMEA/H/C/004750

AveXis Netherlands B.V.; treatment of spinal muscular atrophy (SMA)

Scope: SmPC

Action: for discussion

2.7. New applications

2.8. Withdrawal of initial marketing authorisation application

2.8.1. Viable T-cells - Orphan - EMEA/H/C/002397

Kiadis Pharma Netherlands B.V.; adjunctive treatment in haematopoietic stem cell transplantation (HSCT) for a malignant disease

Scope: Withdrawal of the MAA

Action: for information

List of Outstanding Issues adopted on 21.06.2019, 14.09.2018, 25.05.2018. List of Questions adopted on 08.09.2017. Oral explanation took place on 10.10.2019.

CAT noted the withdrawal letter from the applicant dated 6 November 2019. The decision to withdraw, as indicated by the applicant in the letter, was that CAT and CHMP considered that the data provided were not sufficiently mature to conclude on the benefit risk balance of the product.

EMA informed CAT that after the CHMP meeting, a question and answer on the withdrawal of Luxceptar will be published together with the withdrawal letter from the applicant. The withdrawal public assessment report will be published at a later stage.

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items

2.10. GMP and GCP inspections requests

No items

2.11. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

2.11.1. Alofisel - darvadstrocel - Orphan - EMEA/H/C/004258/II/0009

Takeda Pharma A/S

Rapporteur: Lisbeth Barkholt

Scope: quality. Request for supplementary information (RSI).

Action: for adoption

Feedback was provided from the discussion in BWP. CAT agreed with the proposed RSI, which was adopted.

2.11.2. Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/II/0014

Novartis Europharm Limited

Rapporteur: Rune Kjeken

Scope: quality. Request for supplementary information (RSI).

Action: for adoption

Feedback was provided from the discussion in BWP. CAT agreed with the RSI proposed. The RSI was adopted.

2.12. Other Post-Authorisation Activities

2.12.1. Holoclar - ex vivo expanded autologous human corneal epithelial cells containing stem cells - Orphan - EMEA/H/C/002450/R/0026

Chiesi Farmaceutici S.p.A.

Rapporteur: Egbert Flory; CHMP Coordinator: Jan Mueller-Berghaus; PRAC Rapporteur: Julie Williams

Scope: 5th annual reassessment for the renewal of marketing authorisation. Opinion

Action: for adoption

The Rapporteur mentioned that the MAH has responded adequately to the RSI adopted at the October 2019 CAT meeting. CAT noted the extension of due data for the specific obligation 1 (final report of the ongoing study HLSTM03[1]). The renewal was adopted.

2.12.2. Strimvelis - autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence - Orphan - EMEA/H/C/003854/ANX/004.2

Orchard Therapeutics (Netherlands) BV

Rapporteur: Sol Ruiz, CHMP Coordinator: Greg Markey

Scope: PASS interim study report / Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) Registry for Patients Treated with Strimvelis™ (or GSK2696273) Gene Therapy: Long-Term Prospective, Non-Interventional Follow-up of Safety and Effectiveness. PRAC advice to CAT.

Action: for discussion

The CAT discussed the PRAC Rapporteur assessment of the RSI to the non-interventional imposed PASS first interim study report. CAT discussed the outcome of the assessment . It was agreed to communicate the CAT position to the PRAC regarding the post-authorisation measure.

2.12.3. Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/ANX/009.1

Novartis Europharm Limited

Rapporteur: Rune Kjeken

[1] Multinational, multicentre, prospective, open-label, uncontrolled interventional study (HLSTM03 hereinafter referred as HOLOCORE or CCD-GPLSCD01-03) to assess the efficacy and safety of autologous cultivated limbal stem cells grafting for restoration of corneal epithelium in patients with limbal stem cell deficiency due to ocular burns.

Scope: Pharmacovigilance: Submission of the protocol for study CCTL019H2301, a randomized open-label parallel-group multicenter Phase III trial to evaluate the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory B-cell aggressive NHL after failure of rituximab and anthracycline containing first-line immunochemotherapy. Study data will support further characterization of the benefit-risk ratio of tisagenlecleucel in an earlier line of DLBCL. PRAC assessment report.

Action: for adoption

The outcome of PRAC assessment of the protocol was presented. CAT was in agreement with the PRAC conclusion.

2.12.4. Yescarta – axicabtagene ciloleucel – Orphan – EMEA/H/C/4480 - EMEA/G/C/PSUSA/00010703/201904

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus; PRAC Rapporteur: Anette Kirstine-Stark

Scope: Pharmacovigialnce: evaluation of a PSUSA procedure. PRAC recommendation

Action: for adoption

The PRAC outcome of the PSUR assessment was presented, as well as the changes proposed for section 4.8 of the SmPC and corresponding changes in the product leaflet (PL). CAT also agreed on additional corrections to the PL, not linked to the assessment of the PSUR (alignment of PL to the SmPC).

3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinion

No items

3.2. Day 60 Evaluation Reports

No items

3.3. New Applications

4. Scientific Recommendation on Classification of ATMPs

4.1. New requests – Appointment of CAT Coordinator

4.1.1. Autologous chondrocytes in suspension - H0005498

Intended for the treatment of knee joint cartilage lesion

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed

4.1.2. Autologous chondrocytes on a fibrinogen carrier – H0005525

Intended for the treatment of knee joint cartilage lesion

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed

4.1.3. MICs - Modulated immune cells – H0005515

Intended for prophylactic use in solid organ transplantation (e.g. kidney transplantation) and therapeutic use in autoimmune disease (e.g. multiple sclerosis)

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed

4.1.4. Wharton's Jelly derived mesenchymal stem cell , Adrenoleukodystrophy – H0005526

Intended for the treatment of adrenoleukodystrophy

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed

4.1.5. Wharton's Jelly derived mesenchymal stem cell , Encephalopathy – H0005527

Intended for the treatment of encephalopathy

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed

4.1.6. Wharton's Jelly derived mesenchymal stem cell , Epilepsy – H0005528

Intended for the treatment of epilepsy

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed

4.1.7. Wharton's Jelly derived mesenchymal stem cell , Osteoarthritis – H0005529

Intended for the treatment of osteoarthritis

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed

4.1.8. Wharton's Jelly derived mesenchymal stem cell , Polyneuropathy – H0005530

Intended for the treatment of polyneuropathy

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed

4.1.9. Wharton's Jelly derived mesenchymal stem cell , Spinal muscular atrophy – H0005531

Intended for the treatment of spinal muscular atrophy

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed

4.1.10. Wharton's Jelly derived mesenchymal stem cell , Spinocerebellar ataxia – H0005532

Intended for the treatment of spinocerebellar ataxia

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed

4.2. Day 30 ATMP scientific recommendation

4.2.1. Recombinant adeno associated viral vector serotype 9 containing the human CLN6 gene – H0005491

Intended for the treatment of neuronal ceroid lipofuscinosis type 6 (CLN6) disease (CLN6 Batten disease)

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 22 November 2019.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.2. Recombinant adeno associated viral vector serotype 9 containing the human CLN3 gene – H0005492

Intended for the treatment of neuronal ceroid lipofuscinosis type 3 (CLN3) disease (CLN3 Batten disease)

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 22 November 2019.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.3. Wharton's Jelly derived mesenchymal stem cell , Alopecia areata – H0005494

Intended for the treatment of alopecia areata

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 22 November 2019.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.4. Wharton's Jelly derived mesenchymal stem cell , Pervasive developmental disorder – H0005502

Intended for the treatment of pervasive developmental disorder

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 22 November 2019.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.5. Wharton's Jelly derived mesenchymal stem cell , Cerebral infarction – H0005503

Intended for the treatment of cerebral infarction

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 22 November 2019.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.6. Wharton's Jelly derived mesenchymal stem cell , Development delay – H0005504

Intended for the treatment of development delay

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 22 November 2019.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.7. Wharton's Jelly derived mesenchymal stem cell , Diabetes - H0005505

Intended for the treatment of diabetes

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 22 November 2019.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.8. Wharton's Jelly derived mesenchymal stem cell , Muscular dystrophy – H0005506

Intended for the treatment of muscular dystrophy

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 22 November 2019.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.9. Wharton's Jelly derived mesenchymal stem cell , Endometrial atrophy – H0005507

Intended for the treatment of endometrial atrophy

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 22 November 2019.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.10. Wharton's Jelly derived mesenchymal stem cell , Multiple sclerosis – H0005508

Intended for the treatment of multiple sclerosis

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 22 November 2019.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.11. Wharton's Jelly derived mesenchymal stem cell , Optic neuropathy – H0005509

Intended for the treatment of optic neuropathy

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 22 November 2019.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.12. Wharton's Jelly derived mesenchymal stem cell , Premature ovarian failure – H0005510

Intended for the treatment of premature ovarian failure

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 22 November 2019.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.13. Wharton's Jelly derived mesenchymal stem cell , Retinitis pigmentosa – H0005511

Intended for the treatment of retinitis pigmentosa

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 22 November 2019.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.14. Wharton's Jelly derived mesenchymal stem cell , Spina bifida – H0005512

Intended for the treatment of spinal bifida

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 22 November 2019.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.15. Wharton's Jelly derived mesenchymal stem cell , Spinal cord injury – H0005513

Intended for the treatment of spinal cord injury

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 22 November 2019.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.16. Wharton's Jelly derived mesenchymal stem cell , Stargardt disease – H0005514

Intended for the treatment of Stargardt disease

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 22 November 2019.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.3. Day 60 revised scientific recommendation (following list of questions)

No items

4.4. Finalisation of procedure

4.4.1. Recombinant adeno-associated virus (AAV) vector based on the AAV serotype hu37 (AAVhu37) expressing human Factor VIII - H0005490

Intended for the treatment of haemophilia A

Scope: no comments raised by the European Commission. Final ATMP scientific recommendation

Action: for information

The information was noted

4.5. Follow-up and guidance

No items

5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests – appointment of CAT Rapporteurs

5.2. CAT reports

5.3. List of Issues

5.4. Finalisation of SA procedures

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

No items

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

6.3.2. Month 1 – Discussion of eligibility

6.3.3. Month 2 – Recommendation of eligibility

6.3.4. Ongoing support

No items

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. Strategic Review & Learning meeting – Helsinki, Finland, 21 – 22 November 2019

CAT: Martina Schüßler-Lenz, Heli Suila

Scope: draft agenda of the joint PDCO-COMP-CAT strategic review and learning meeting (SRLM)

Action: for discussion

CAT agreed with the agenda for the upcoming SRLM. Some CAT members were interested to join remotely: further information will be provided to CAT via e-mail.

7.1.2. Strategic Review & Learning meeting – joint CAT/Clinical trial facilitation group (CTFG), Bucharest, Romania, June 2019

CAT: Simona Badoi

Scope: minutes from the SRLM meeting

Action: for information

A short oral feedback was provided in July 2019.

Comments from CAT members on the minutes of the SRLM meeting are awaited . A final presentation of the minutes will take place at the December CAT meeting.

7.2. Coordination with EMA Scientific Committees

7.2.1. Committee for Medicinal Products for Human Use (CHMP)

Scope: Summary of Outcomes (SoO) for the October 2019 meeting

Action: for information

The information was noted.

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. Questions & Answers on comparability

CAT drafting group: Margarida Menezes, Ilona Reischl, Ivana Haunerová, Heli Suila, Barbara Bonamassa

Scope: draft questions and answers document

Action: for information

Note: the document is for adoption by CAT at its December 2019 meeting.

The latest version of the Q&A was noted. The Q&A was presented to BWP for their comments .

7.4. Cooperation within the EU regulatory network

No items

7.5. Cooperation with international regulators

7.5.1. ATMP cluster teleconference with FDA-USA, Health Canada and PMDA-Japan

The teleconference will take place on Thursday 14 November, 15:00 – 16:00hrs

Scope: draft agenda

Action: for discussion

Members interested to join this ATMP cluster TC should inform CAT Secretariat .

7.5.2. International Pharmaceutical Regulators Programme (IPRP) – Gene therapy working group

CAT: Pille Säälik

Scope: feedback on the teleconference that took place on 23 October 2019

Action: for information

Feedback was provided from the last IPRP teleconference.

7.6. CAT work plan

7.6.1. CAT work plan 2020

CAT: Martina Schüßler-Lenz

Action: for discussion

The latest version of the work plan was noted. CAT members interested to take part in one of the planned activities should inform CAT Secretariat . Adoption of the CAT work plan for 2020 is scheduled for the December CAT meeting.

7.7. Planning and reporting

No items

7.8. Others

7.8.1. CAT regulatory session at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), 25 October 2019, Barcelona (Spain)

CAT: Martina Schüssler-Lenz, Jan Müller-Berghaus, Anne Pastoft, Heli Suila

Scope: feedback on the CAT session at the ESGCT annual congress

Action: for information

Topic postponed until the December CAT meeting.

7.8.2. Curriculum on Advanced Therapies Medicinal Products (ATMPs) - training session on quality aspects for cell-based medicinal products

CAT: Margarida Menezes Ferreira

Scope: training session on quality aspects for cell-based medicinal products

The proposal to invite Margarida Menezes Ferreira to give a training on the above topic in the margins of the January or February 2020 CAT meeting was agreed.

Action: for information

8. Any other business

8.1.1. EMA relocation to the permanent building, Amsterdam, The Netherlands

Scope: update on planned timelines

Action: for information

Feedback was provided on the relocation to the EMA building in Amsterdam in January 2020. A dedicated e-mail with an orientation guide will be sent to all CAT members.

8.1.2. Heads of Medicines Agencies (HMA)-EMA joint big data taskforce - draft recommendations

Scope: HMA-EMA Joint Big Data Taskforce summary report

Action: for discussion

A presentation was given on the recommendation coming from the EMA joint big data task force. There was a discussion on the implementation of the recommendation made.

8.1.3. Update on EMA organisational aspects

Action: for information

A presentation was given on EMA organisational aspects.

Date of next CAT meeting:
04-06 December 2019

9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Abbreviations / Acronyms

AAV: Adeno-Associated Virus

AR: Assessment Report

ATMP: Advanced Therapy Medicinal Product

BWP: Biologics Working Party

CAT: Committee for Advanced Therapies

CHMP: Committee for Medicinal Product for Human Use

COMP: Committee for Orphan Medicinal Products

CTFG: Clinical Trial Facilitation Group

DG: Drafting Group

EC: European Commission

ERA: Environmental Risk Assessment

FDA: Food and Drug Administration

FL: Final Letter

GCG: Guideline Consistency Group

GCP: Good Clinical Practice

GLP: Good Laboratory Practice

GMO: Genetically-modified organism

GMP: Good Manufacturing Practice

GTMP: Gene Therapy Medicinal Product

HTA: Health Technology Assessment Bodies

HSPC: Hematopoietic Stem and Progenitor Cells

ITF: Innovative Task Force

JR: Joint Report

LoOI: List of outstanding issues

LoQ: List of questions

MA: Marketing Authorisation

MAA: Marketing Authorisation Application

MAH: Marketing Authorisation Holder

MSC: Mesenchymal stem cells

PDCO: Paediatric Committee

PMDA: Pharmaceuticals and Medical Devices Agency (Japan)

PIP: Paediatric Investigation Plan

PL: Package leaflet

PRAC: Pharmacovigilance and Risk Assessment Committee #

PRIME: Priority Medicines

RMP: Risk Management Plan

RP: Reflection paper

RSI: Request for supplementary information

SAs: Scientific Advices

SAG-O: Scientific Advisory Group Oncology

SAWP: Scientific Advice Working Party

SR: Summary Report

SWP: Scientific Working Party

SME: Small and medium size enterprises

SmPC: Summary of Products Characteristics

TT: Timetable

Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists any ATMP related inspection requests (section 2.9) and Post-authorisation activities (section 2.10).

New applications (sections 2.1. to 2.12.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found here.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.3) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures**). Section 2.7 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.6.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has

requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Withdrawal of applications (section 2.7.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

New applications (section 2.9.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

GMP and GCP Inspections Issues (section 2.10.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Post-authorisation activities (section 2.12.)

This section lists type II variations, extension application according to Annex I of Reg. 1234/2008, re-examination procedures for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP and other issues concerning authorised medicines that are not covered elsewhere in the agenda such as annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found here.

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found here.

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found here.

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found here.

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

10. List of participants

including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 06-08 November 2019 meeting.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Martina Schüssler-Lenz	Chair	Germany	No interests declared	
Corina Spreitzer	Alternate	Austria	No interests declared	
Claire Beuneu	Member	Belgium	No interests declared	
Belaïd Sekkali	Alternate	Belgium	No interests declared	
Rozalina Kulaksazova	Member	Bulgaria	No interests declared	
Petra Sokol	Alternate	Croatia	No interests declared	
Rafaella Pontou	Member	Cyprus	No interests declared	
Ondrej Palan	Alternate	Czech Republic	No interests declared	
Anne Pastoft	Member	Denmark	No interests declared	
Toivo Maimets	Member	Estonia	No interests declared	
Pille Saalik	Alternate	Estonia	No interests declared	
Heli Suila	Member	Finland	No interests declared	
Olli Tenhunen	Alternate	Finland	No interests declared	
Violaine Closson	Member	France	No interests declared	
Nathalie Morgensztejn	Alternate	France	No interests declared	
Jan Mueller-Berghaus	Member (CHMP co-opted member)	Germany	No interests declared	
Egbert Flory	Alternate (to CHMP representative)	Germany	No interests declared	
Angeliki Roboti	Alternate	Greece	No interests declared	
Katalin Lengyel	Member	Hungary	No interests declared	
Maura O'Donovan	Member	Ireland	No interests declared	
Giulio	Alternate	Italy	No restrictions	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Pompilio			applicable to this meeting	
Una Riekstina	Member	Latvia	No interests declared	
Romaldas Mačiulaitis	Member (CHMP member)	Lithuania	No interests declared	
Anthony Samuel	Alternate (to CHMP representative)	Malta	No interests declared	
Carla Herberts	Member	Netherlands	No interests declared	
Johannes Hendrikus Ovelgonne	Alternate	Netherlands	No interests declared	
Rune Kjeken	Member	Norway	No restrictions applicable to this meeting	
Maja Sommerfelt Grønvold	Alternate	Norway	No restrictions applicable to this meeting	
Dariusz Śladowski	Member	Poland	No restrictions applicable to this meeting	
Margarida Menezes-Ferreira	Alternate (to CHMP representative)	Portugal	No interests declared	
Simona Badoi	Member	Romania	No interests declared	
Lukas Slovak	Member	Slovakia	No interests declared	
Metoda Lipnik-Stangelj	Member	Slovenia	No interests declared	
Marcos Timón	Alternate (to CHMP representative)	Spain	No interests declared	
Lisbeth Barkholt	Member	Sweden	No interests declared	
John Johnston	Member	United Kingdom	No interests declared	
Bernd Gänsbacher	Member	Healthcare Professionals' Representative	No interests declared	
Alessandro Aiuti	Member	Healthcare Professionals' Representative	No participation to final discussion	Strimvelis
Alessandra Renieri	Alternate	Healthcare Professionals'	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
		Representative		
Kerstin Sollerbrant	Member	Patients' Representative	No interests declared	
Kieran Breen	Member	Patients' Representative	No restrictions applicable to this meeting	
Roland Pochet	Alternate	Patients' Representative	No interests declared	
Maren Hammann	Expert - via telephone*	PEI-DE	No interests declared	
Andreea Barbu	Expert - via telephone*	MPA-SE	No restrictions applicable to this meeting	No restrictions for Alofisel
A representative from the European Commission attended the meeting				
Meeting run with support from relevant EMA staff				

* Experts were only evaluated against the agenda topics or activities they participated in.